입체선택성 2,4,6-삼치환된 테트라하이드로파이란 유도체 및 이의 제조방법
    142.
    发明公开
    입체선택성 2,4,6-삼치환된 테트라하이드로파이란 유도체 및 이의 제조방법 有权
    二异氰酸酯选择性2,4,6-取代的四氢化Y嗪及其制备方法

    公开(公告)号:KR1020150109214A

    公开(公告)日:2015-10-01

    申请号:KR1020140032364

    申请日:2014-03-19

    CPC classification number: C07D309/04 C07D309/08 C07D309/24

    Abstract: 본발명은입체선택성 2,4,6-삼치환된테트라하이드로파이란유도체및 이의제조방법에관한것으로, 더욱상세하게는 2-메틸렌-1,4-다이올유도체를출발물질로하고루이스산촉매를이용한분자간고리화반응을수행하여, C2, C4 및 C6 위치에동시에치환기가도입된입체선택성 2,4,6-삼치환된테트라하이드로파이란유도체및 이의제조방법에관한것이다.

    Abstract translation: 本发明涉及立体选择性2,4,6-三取代四氢吡喃衍生物及其制备方法,更具体地说,涉及立体选择性2,4,6-三取代四氢吡喃衍生物及其制备方法,其中衍生物用途 2-亚甲基1,4-二醇衍生物作为原料,并使用路易斯酸催化剂进行分子间循环反应,其中取代基同时引入C_2,C_4和C_6的位置。

    미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
    145.
    发明公开
    미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체 有权
    苯并咪唑衍生物作为麻醉功能调节剂

    公开(公告)号:KR1020140050802A

    公开(公告)日:2014-04-30

    申请号:KR1020120117057

    申请日:2012-10-22

    Abstract: The present invention relates to a benzimidazole derivative which has pharmaceutical activity as a neuroprotective agent by modulating mitochondrial functions and a pharmaceutical composition comprising the same as an active ingredient. The benzimidazole derivative or a pharmaceutically acceptable salt thereof, according to the present invention, has an excellent activity as a neuroprotective agent affecting mitochondria, thereby can be used as a medicine for diseases such as Alzheimer′s disease, Parkinson′s disease, Huntington′s disease, ischemic brain disease, diabetes, and schizophrenia.

    Abstract translation: 本发明涉及通过调节线粒体功能而具有作为神经保护剂的药学活性的苯并咪唑衍生物和包含其作为活性成分的药物组合物。 根据本发明的苯并咪唑衍生物或其药学上可接受的盐作为影响线粒体的神经保护剂具有优异的活性,因此可以用作诸如阿尔茨海默氏病,帕金森病,亨廷顿病, 缺血性脑病,糖尿病和精神分裂症。

    항암활성을 지닌 카르보아졸계 화합물
    147.
    发明公开
    항암활성을 지닌 카르보아졸계 화합물 有权
    具有抗癌活性的新型咔唑类化合物

    公开(公告)号:KR1020120056684A

    公开(公告)日:2012-06-04

    申请号:KR1020100118341

    申请日:2010-11-25

    Abstract: PURPOSE: A carboazole-based compounds with an anticancer activity and a method for preparing the same are provided to prevent and treat cancer. CONSTITUTION: A carboazole-based compound with an anticancer activity is denoted by chemical formula 1. A pharmaceutical composition for anticancer contains the carboazole-based compounds of chemical formula 1. A method for preparing the carboazole-based compounds comprises: a step of reacting amidation of heterocyclic compounds of chemical formula III with 4-haloazole compounds of chemical formula IV to prepare a 4-halocaboazole-based compound of chemical formula V; and a step of performing Suzuki coupling of the compound of chemical formula V with a boronic acid compound of chemical formula VI.

    Abstract translation: 目的:提供具有抗癌活性的基于咔唑的化合物及其制备方法,以预防和治疗癌症。 构成:具有抗癌活性的基于唑的化合物由化学式1表示。用于抗癌的药物组合物含有化学式1的咔唑类化合物。一种制备该类咔唑类化合物的方法包括:使酰胺化反应 的化学式III的4-卤唑化合物的化学式III的杂环化合物,以制备化学式V的4-卤代咔唑类化合物; 以及化学式V化合物与化学式VI的硼酸化合物的Suzuki偶联的步骤。

    GSK-3 억제활성을 보이는 1H-인다졸 화합물
    148.
    发明公开
    GSK-3 억제활성을 보이는 1H-인다졸 화합물 有权
    具有GSK-3抑制活性的1H-吲唑化合物

    公开(公告)号:KR1020120038033A

    公开(公告)日:2012-04-23

    申请号:KR1020100097910

    申请日:2010-10-07

    Abstract: PURPOSE: A 1H-indazole compound with GSK3 inhibition and pharmaceutically acceptable salt thereof are provided to be used as a therapeutic agent for treating diseases caused by GSK-3 activation. CONSTITUTION: A 1H-indazole compounds is denoted by chemical formula 1. A method for preparing the compound comprises: a step of performing amidation of 3-amino-1H-indazole compounds of chemical formula 2 and a substituted carboxylic acid compound of chemical formula 3 under the presence of pyridine base and 1-ethyl-3-(3'-dimethyl aminopropyl)carbodiimide hydrochloride(EDCI).

    Abstract translation: 目的:提供具有GSK3抑制的1H-吲唑化合物及其药学上可接受的盐作为治疗由GSK-3激活引起的疾病的治疗剂。 构成:1H-吲唑化合物由化学式1表示。一种制备化合物的方法包括:进行化学式2的3-氨基-1H-吲唑化合物和化学式3的取代的羧酸化合物的酰胺化步骤 在吡啶碱和1-乙基-3-(3'-二甲基氨基丙基)碳二亚胺盐酸盐(EDCI)的存在下。

Patent Agency Ranking